Drug Class Info

Question 1

NRTIs

Answer 1

• drugs: abacavir, didanosine, emtricitabine, lamivudine, stavudine, tenofovir, zidovudine
• MOA: compete at reverse transcription to interfere w/ RNA-dependent DNA polymerase–> chain termination
• BBW: lactic acidosis, severe hepatomegaly w/ steatosis
• DDI: don’t undergo hepatic transformation via CYP pathway

Question 2

NNRTIs

Answer 2

• efavirenz, etravirine, nevirapine, rilpivirine
• MOA: non-competitive binding to reverse transcriptase to interfere w/ RNA/DNA-dependent DNA polymerase–> chain termination
• SE: rash (SJS/TENS), hepatotoxicity
• DDI: all are 3A4 substrates and can also be inducers, inhibitors, or both

Question 3

PIs

Answer 3

• atazanavir, daruvanivr, fosamprenavir, indinavir, lopinavir, nelfinavir, ritonavir, saquinavir, tipranavir
• SE: hyperglycemia, lipohypertrophy, hyperlipidemia, hepatitis, increased CVD risk, EKG changes
• DDI: all are 3A4 substrates and most are strong 3A4 inhibitors, decrease INR, increase PDE5 inhibitors, lova/simva use CI

Question 4

CCR5 antagonist

Answer 4

• maraviroc
• MOA: binding to prevent cell entry (step 1 of cycle)
• BBW: hepatotoxicity
• DDI: major 3A4 substrate, P-gp

Question 5

IIs

Answer 5

• dolutegravir, elvitegravir, raltegravir
• MOA: integrase strand transfer inhibitition
• DDI: take 2 hrs before or 6 hrs after cations/Fe/Ca

Question 6

Relative antiinflammatory potency of PO CCSs

Answer 6

betamethasone/dexamethasone>methylprednisolone/triamcinolone>prednisone/prednisolone>hydrocortisone>cortisone